4-(m-chlorophenyl)-1-butanol | 75906-35-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(m-chlorophenyl)-1-butanol
• 英文别名: 4-(3-chlorophenyl)-1-butanol；4-(3-chlorophenyl)butan-1-ol
• CAS: 75906-35-3
• 化学式: C₁₀H₁₃ClO
• 分子量: 184.666
• InChiKey: YBUZVYGUBQXUBI-UHFFFAOYSA-N

物化性质

• 沸点：
  292.0±23.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  ethyl 4-{1-(2-ethoxy-2-oxoethyl)-7-[(E)-2-(4-hydroxyphenyl)vinyl]-1H-indol-3-yl}butanoate 、 4-(m-chlorophenyl)-1-butanol 在 三苯基膦 、 1,1'-azodicarbonyl-dipiperidine 作用下， 以 二氯甲烷 为溶剂， 反应 15.0h， 生成
  参考文献：
  名称：

  Discovery of Gemilukast (ONO-6950), a Dual CysLT₁ and CysLT₂ Antagonist As a Therapeutic Agent for Asthma

  摘要：

  An orally active dual CysLT(1) and CysLT(2) antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT(1) and human CysLT(2), respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT(1)-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT(1)- and CysLT(2)-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.

  DOI：

  10.1021/acs.jmedchem.5b00741
• 作为产物：
  描述：

  3-氯苄溴 在 9-硼双环[3.3.1]壬烷 作用下， 以 四氢呋喃 、 乙醚 、 正己烷 为溶剂， 生成 4-(m-chlorophenyl)-1-butanol
  参考文献：
  名称：

  由手性阳离子引导的对映选择性分子间 C-H 胺化

  摘要：

  C( sp 3 )-H 键的对映选择性胺化是一种强大的合成转化，但在分子间意义上实现却极具挑战性。我们开发了一系列用于 Rh 催化的 C–H 胺化的一流催化剂的阴离子变体，Rh 2 (esp) 2，我们将衍生自季铵化金鸡纳生物碱的手性阳离子与它们相关联。这些离子对催化剂能够在带有侧羟基的底物的苄基 C-H 胺化中实现高水平的对映选择性。此外，手性阳离子的喹啉似乎与铑络合物进行轴向连接，与 Rh 2 (esp) 2相比，提供了更高的产物产率并突出阳离子所发挥的双重作用。这些结果强调了使用手性阳离子在具有挑战性的过渡金属催化转化中控制对映选择性的潜力。

  DOI：

  10.1021/jacs.1c05206

文献信息

• [EN] ALPHA-HYDROXY PHENYLACETIC ACID PHARMACOPHORE OR BIOISOSTERE MCL-1 PROTEIN ANTAGONISTS<br/>[FR] PHARMACOPHORES D'ACIDE ALPHA-HYDROXY PHÉNYLACÉTIQUE OU ANTAGONISTES DE LA PROTÉINE BIO-ISOSTÈRE MCL-1
  申请人：AMGEN INC

  公开号：WO2019173181A1

  公开（公告）日：2019-09-12

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓系细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用它们的方法。例如，本文提供了化合物I的结构，或其立体异构体；以及其药用盐和含有该化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。
• Antituberculous composition comprising oxazole compounds
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP2269694A2

  公开（公告）日：2011-01-05

  The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R2 represents general formula (A) or the like, wherein R represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as secondary antituberculous drugs.

  本发明提供了效力更高的抗结核治疗药物。本发明还提供了含有由(I)通式(1)代表的噁唑化合物的抗结核治疗药物：[其中R1代表氢原子或C1-6烷基，n代表0-6的整数，R2代表通式(A)或类似物，其中R代表苯氧基（至少一个选自卤素原子、任选卤素取代的C1-6烷基和任选卤素取代的C1-6烷氧基组成的组中的基团可在苯基环上被取代）或类似物]，其光学活性形式或其盐，以及药物(II)如二级抗结核药物。
• ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS
  申请人：Matsumoto Makoto

  公开号：US20090275528A1

  公开（公告）日：2009-11-05

  The present invention provides antituberculous therapeutic drugs with a higher potency. The present invention provides also antituberculous therapeutic drugs containing oxazole compounds represented by (I) general formula (1): [wherein R 1 represents a hydrogen atom or C1-6 alkyl group, n represents an integer of 0-6, and R 2 represents general formula (A) or the like, wherein R 3 represents a phenoxy group (at least one group selected from the group consisting of a halogen atom, an optionally halogen-substituted C1-6 alkyl group and an optionally halogen-substituted C1-6 alkoxy group may be substituted on the phenyl ring) or the like], optically active forms thereof or salts thereof, and drugs (II) such as primary antituberculous drugs.
• US8987304B2
  申请人：——

  公开号：US8987304B2

  公开（公告）日：2015-03-24
• Discovery of Gemilukast (ONO-6950), a Dual CysLT₁ and CysLT₂ Antagonist As a Therapeutic Agent for Asthma
  作者：Satoshi Itadani、Kentaro Yashiro、Yoshiyuki Aratani、Tetsuya Sekiguchi、Atsushi Kinoshita、Hideki Moriguchi、Nobukazu Ohta、Shinya Takahashi、Akiharu Ishida、Yohei Tajima、Katsuya Hisaichi、Masaki Ima、Junya Ueda、Hiromu Egashira、Tomohiko Sekioka、Michiaki Kadode、Yasuo Yonetomi、Takafumi Nakao、Atsuto Inoue、Hiroaki Nomura、Tetsuya Kitamine、Manabu Fujita、Takeshi Nabe、Yoshiyuki Yamaura、Naoya Matsumura、Akira Imagawa、Yoshisuke Nakayama、Jun Takeuchi、Kazuyuki Ohmoto

  DOI：10.1021/acs.jmedchem.5b00741

  日期：2015.8.13

  An orally active dual CysLT(1) and CysLT(2) antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT(1) and human CysLT(2), respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT(1)-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT(1)- and CysLT(2)-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.